Supernus Pharmaceuticals (SUPN) Upgraded by Janney Montgomery Scott to Buy

Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a neutral rating to a buy rating in a research report sent to investors on Monday morning. Janney Montgomery Scott currently has $47.00 price objective on the specialty pharmaceutical company’s stock.

Other equities analysts have also recently issued reports about the company. Stifel Nicolaus cut Supernus Pharmaceuticals from a buy rating to a hold rating and set a $47.00 price target for the company. in a report on Tuesday, September 19th. They noted that the move was a valuation call. Piper Jaffray Companies reiterated a hold rating and set a $45.00 price target on shares of Supernus Pharmaceuticals in a report on Friday, September 8th. Cowen set a $50.00 price target on Supernus Pharmaceuticals and gave the stock a buy rating in a report on Monday, October 23rd. Jefferies Group reiterated a buy rating and set a $51.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, September 20th. Finally, Zacks Investment Research upgraded Supernus Pharmaceuticals from a hold rating to a strong-buy rating and set a $47.00 price target for the company in a report on Wednesday, November 8th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $49.60.

Shares of Supernus Pharmaceuticals (NASDAQ SUPN) traded down $0.05 on Monday, hitting $37.15. The company’s stock had a trading volume of 465,400 shares, compared to its average volume of 609,007. Supernus Pharmaceuticals has a twelve month low of $21.50 and a twelve month high of $50.04. The firm has a market cap of $1,906.95, a P/E ratio of 35.09, a PEG ratio of 1.57 and a beta of 1.19.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings results on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. The business had revenue of $80.40 million during the quarter, compared to analysts’ expectations of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The firm’s quarterly revenue was up 41.5% on a year-over-year basis. equities analysts predict that Supernus Pharmaceuticals will post 1.07 earnings per share for the current fiscal year.

In other news, SVP Padmanabh P. Bhatt sold 5,000 shares of Supernus Pharmaceuticals stock in a transaction dated Friday, September 8th. The stock was sold at an average price of $49.86, for a total value of $249,300.00. Following the completion of the transaction, the senior vice president now owns 12,500 shares in the company, valued at approximately $623,250. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Stefan K.F. Schwabe sold 95,000 shares of Supernus Pharmaceuticals stock in a transaction dated Thursday, September 7th. The shares were sold at an average price of $46.59, for a total value of $4,426,050.00. The disclosure for this sale can be found here. Insiders have sold a total of 150,000 shares of company stock valued at $7,055,350 over the last 90 days. 6.70% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Pinebridge Investments L.P. boosted its stake in shares of Supernus Pharmaceuticals by 1.3% in the 2nd quarter. Pinebridge Investments L.P. now owns 6,624 shares of the specialty pharmaceutical company’s stock valued at $285,000 after buying an additional 86 shares during the period. Arizona State Retirement System boosted its stake in shares of Supernus Pharmaceuticals by 0.4% in the 2nd quarter. Arizona State Retirement System now owns 26,201 shares of the specialty pharmaceutical company’s stock valued at $1,129,000 after buying an additional 100 shares during the period. The Manufacturers Life Insurance Company boosted its stake in shares of Supernus Pharmaceuticals by 0.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 36,650 shares of the specialty pharmaceutical company’s stock valued at $1,579,000 after buying an additional 128 shares during the period. CS Mckee LP boosted its stake in shares of Supernus Pharmaceuticals by 0.5% in the 2nd quarter. CS Mckee LP now owns 42,050 shares of the specialty pharmaceutical company’s stock valued at $1,812,000 after buying an additional 200 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of Supernus Pharmaceuticals by 0.3% in the 2nd quarter. Rhumbline Advisers now owns 93,907 shares of the specialty pharmaceutical company’s stock valued at $4,047,000 after buying an additional 288 shares during the period. Institutional investors and hedge funds own 98.34% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Community Financial News and is owned by of Community Financial News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.com-unik.info/2017/12/05/supernus-pharmaceuticals-supn-upgraded-by-janney-montgomery-scott-to-buy.html.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

What are top analysts saying about Supernus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Supernus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit